Physician profile
Tiffany Marie Linville
NPI 1205910734
$69,788.43
in general payments reported to CMS, 2019-2025
12 companies · $17K in 2025
The $17K reported for 2025 was more than what 96% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $6,428 · 2021: $16K · 2022: $6,394 · 2023: $993 · 2024: $680 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $8,800 · Consulting Fee: $6,831 · Food and Beverage: $2,604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $8,800.00 |
| Consulting Fee | $6,831.00 |
| Food and Beverage | $2,603.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $52,631.40 | 2019-2025 | |
| Celltrion USA INC. | $9,294.50 | 2025 | Zymfentra, Vegzelma |
| Takeda Pharmaceuticals U.S.A., INC. | $6,838.99 | 2025 | |
| Janssen Biotech, INC. | $476.82 | 2022-2025 | Stelara, Tremfya, Remicade |
| Janssen Scientific Affairs, LLC | $264.60 | 2019-2024 | Stelara |
| Regeneron Healthcare Solutions, INC. | $125.01 | 2022 | |
| Pfizer INC. | $100.00 | 2021-2024 | |
| Nestle Healthcare Nutrition INC. | $38.56 | 2021 | |
| Sandoz INC. | $17.77 | 2024 | Hyrimoz |
| Travere Therapeutics, INC. | $0.78 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Linville listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.